Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Beneish M-Score: -1.76 (As of Jul. 06, 2026)


CAI:RMDA Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA
84 GF Score
Price E£5.10
GF Value E£4.08
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Beneish M-Score?

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA +1.80% 84 Beneish M-Score is -1.76 as of Jul. 06, 2026. GuruFocus rates CAI:RMDA with a GF Score™ of 84/100 and a GF Value™ of E£4.08 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 910 Drug Manufacturers companies, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks worse than 85.49% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.76 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Beneish M-Score or its related term are showing as below:

CAI:RMDA' s Beneish M-Score Range Over the Past 10 Years
Min: -2.28   Med: -1.72   Max: -1.31
Current: -1.76

During the past 8 years, the highest Beneish M-Score of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents was -1.31. The lowest was -2.28. And the median was -1.72.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Beneish M-Score Chart

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -2.20 -1.88 -1.62 -1.65 -1.65

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.65 -1.31 -1.36 -1.65 -1.76

CAI:RMDA vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Beneish M-Score falls into.


CAI:RMDA
84GF Score
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1929+0.528 * 0.956+0.404 * 0.9246+0.892 * 1.3521+0.115 * 1.1554
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2462+4.679 * 0.07295-0.327 * 1.1107
=-1.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was E£2,322 Mil.
Revenue was 1066.778 + 1132.311 + 1134.754 + 963.332 = E£4,297 Mil.
Gross Profit was 526.728 + 592.392 + 516.456 + 470.034 = E£2,106 Mil.
Total Current Assets was E£3,409 Mil.
Total Assets was E£5,306 Mil.
Property, Plant and Equipment(Net PPE) was E£789 Mil.
Depreciation, Depletion and Amortization(DDA) was E£93 Mil.
Selling, General, & Admin. Expense(SGA) was E£521 Mil.
Total Current Liabilities was E£2,904 Mil.
Long-Term Debt & Capital Lease Obligation was E£72 Mil.
Net Income was 102.756 + 30.173 + 97.603 + 88.445 = E£319 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = E£0 Mil.
Cash Flow from Operations was 98.929 + 34.894 + 93.622 + -295.551 = E£-68 Mil.
Total Receivables was E£1,440 Mil.
Revenue was 865.617 + 984.32 + 763.229 + 564.906 = E£3,178 Mil.
Gross Profit was 402.661 + 468.147 + 347.088 + 270.789 = E£1,489 Mil.
Total Current Assets was E£2,856 Mil.
Total Assets was E£4,497 Mil.
Property, Plant and Equipment(Net PPE) was E£626 Mil.
Depreciation, Depletion and Amortization(DDA) was E£87 Mil.
Selling, General, & Admin. Expense(SGA) was E£309 Mil.
Total Current Liabilities was E£2,264 Mil.
Long-Term Debt & Capital Lease Obligation was E£7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2322.177 / 4297.175) / (1439.729 / 3178.072)
=0.540396 / 0.45302
=1.1929

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1488.685 / 3178.072) / (2105.61 / 4297.175)
=0.468424 / 0.489999
=0.956

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3409.076 + 789.424) / 5306.147) / (1 - (2856.366 + 625.647) / 4497.347)
=0.208748 / 0.225763
=0.9246

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4297.175 / 3178.072
=1.3521

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(86.922 / (86.922 + 625.647)) / (93.185 / (93.185 + 789.424))
=0.121984 / 0.105579
=1.1554

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(521.083 / 4297.175) / (309.244 / 3178.072)
=0.121262 / 0.097306
=1.2462

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((72.157 + 2904.005) / 5306.147) / ((6.772 + 2264.385) / 4497.347)
=0.560889 / 0.504999
=1.1107

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(318.977 - 0 - -68.106) / 5306.147
=0.07295

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a M-score of -1.76 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.76 mean?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a Beneish M-Score of -1.76 as of Jul. 06, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. According to the industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #778 out of 910 companies in the Drug Manufacturers industry, placing it in the top 85.5%.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Beneish M-Score too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current Beneish M-Score is -1.76. Based on the distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #778 out of 910 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #778 out of 910 companies for Beneish M-Score. This places Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Beneish M-Score is -1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Modestly Overvalued. The stock's GF Value™ is E£4.08, compared to a current price of E£5.10 — trading 25% above its estimated fair value. The current Beneish M-Score is -1.76. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current Beneish M-Score is -1.76 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?

Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued. The current stock price of E£5.10 is trading 25% above its estimated GF Value™ of E£4.08. GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Modestly Overvalued.

Key valuation signals for CAI:RMDA:

  • Beneish M-Score: -1.76
  • GF Value™: E£4.08 vs. price of E£5.10 (25% above fair value)
  • GF Score™: 84/100 with 9 warning signs

No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Business Description

Address No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
84GF Score

Get the complete analysis for CAI:RMDA

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£5.10
Price
E£4.08
GF Value